Literature DB >> 8396506

Protein kinase C and calcium channel activation as determinants of renal vasoconstriction by angiotensin II and endothelin.

T Takenaka1, H Forster, M Epstein.   

Abstract

The mechanisms mediating renal microvascular constriction induced by angiotensin II (Ang II) and endothelin (ET) have not been fully established. In the present study, we have determined the effects of isradipine, a dihydropyridine calcium antagonist, on Ang II- or ET-induced constriction of afferent arterioles (AAs) and efferent arterioles (EAs) using the isolated perfused hydronephrotic kidney. Ang II (0.3 nmol/L) and ET (0.3 nmol/L) constricted AAs by 36 +/- 2% and 29 +/- 3%, respectively. Isradipine reversed AA constriction induced by both peptides. However, Ang II-induced AA constriction was more sensitive to isradipine than ET-induced constriction (half-maximal inhibitory concentration [IC50], 1.2 +/- 0.2 nmol/L [n = 12] versus 170 +/- 65 nmol/L [n = 19]; P < .01). The sensitivity of Ang II-induced AA constriction to isradipine was identical to that of KCI-induced AA constriction (IC50, 4.2 +/- 0.9 nmol/L; n = 12). Pretreatment with staurosporine (50 nmol/L), a protein kinase C inhibitor, enhanced the sensitivity of ET-induced AA constriction to isradipine (4.3 +/- 1.7 nmol/L, n = 14), rendering it identical to that of KCl-induced AA constriction. Ang II and ET decreased EA diameter by 26 +/- 2% (n = 12) and 12 +/- 2% (n = 8), respectively. In contrast to AA constriction, EA constriction induced by both peptides was relatively refractory to isradipine.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396506     DOI: 10.1161/01.res.73.4.743

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  12 in total

1.  Cellular mechanisms mediating rat renal microvascular constriction by angiotensin II.

Authors:  T Takenaka; H Suzuki; K Fujiwara; Y Kanno; Y Ohno; K Hayashi; T Nagahama; T Saruta
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

Review 2.  Physiology of endothelin and the kidney.

Authors:  Donald E Kohan; Edward W Inscho; Donald Wesson; David M Pollock
Journal:  Compr Physiol       Date:  2011-04       Impact factor: 9.090

Review 3.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

Review 4.  ET-1 actions in the kidney: evidence for sex differences.

Authors:  W Kittikulsuth; J C Sullivan; D M Pollock
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

Review 5.  Endothelin and the renal microcirculation.

Authors:  Zhengrong Guan; Justin P VanBeusecum; Edward W Inscho
Journal:  Semin Nephrol       Date:  2015-03       Impact factor: 5.299

6.  Electrophysiological effects of endothelin-1 and their relationship to contraction in rat renal arterial smooth muscle.

Authors:  L C Betts; R Z Kozlowski
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

7.  Mechanisms of angiotensin II chronotropic effect in anaesthetized dogs.

Authors:  C Lambert
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

8.  Rho-kinase inhibition reduces pressure-mediated autoregulatory adjustments in afferent arteriolar diameter.

Authors:  Edward W Inscho; Anthony K Cook; R Clinton Webb; Li-Ming Jin
Journal:  Am J Physiol Renal Physiol       Date:  2009-01-07

9.  Olmesartan improves endothelin-induced hypertension and oxidative stress in rats.

Authors:  Li Yao; Hiroyuki Kobori; Matlubur Rahman; Dale M Seth; Takatomi Shokoji; Yuyan Fan; Guo-Xing Zhang; Shoji Kimura; Youichi Abe; Akira Nishiyama
Journal:  Hypertens Res       Date:  2004-07       Impact factor: 3.872

Review 10.  Isradipine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.